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Schwannomatosis is a form of Neurofibromatosis type 2
(NF2) characterized by multiple schwannomas without
vestibular involvement, affecting the cranium, spine and
periphery. Several recent genetic studies have implicated
the SMARCB1/INI1 tumour suppressor gene in familial
schwannomatosis. SMARCB1 is located centromeric to
NF2 on 22q and loss of function of SMARCB1 is also a
hallmark of malignant rhabdoid tumour (MRT), a highly
aggressive tumour of infancy. Both familial and sporadic
schwannoma tumours show a mosaic pattern of
SMARCB1 protein expression, suggestive of tumour
cells either haploinsufficient, or null for SMARCB1 pro-
tein. Familial schwannomas linked to constitutional
SMARCB1 mutation can also have somatic mutation of
NF2, and conversely, schwannoma tumours associated
with constitutional NF2 mutation show mosaic loss of
SMARCB1, suggesting the involvement of a four-hit
mechanism. Molecular analysis for evidence of constitu-
tional SMARCB1 mutation is important in both familial
and sporadically occurring schwannomatosis because of
the transmission risk for a mutation predisposing to the
incurable MRT, in early childhood. However as for NF2,
recent evidence suggests that constitutional SMARCB1
mutations have variable penetrance and exhibit mosai-
cism, highlighting the importance of examining multiple
tumour tissue samples as well as blood in affected indi-
viduals to ascertain germline predisposition and to pro-
vide accurate counseling for transmission risk. Further
studies are needed to define the SMARCB1 mutation
spectrum in schwannomatosis and to dissect the strik-
ingly different biology between schwannoma and MRT.
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